Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGT-303 in Healthy Volunteers and Chronic Kidney Disease
NCT07231679Phase 2Recruiting
- Sponsor
- INGENIA Therapeutics
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Biologic
- Countries
- 4
01
Overview
A Phase 2 trial of IGT-303 in chronic kidney disease (CKD), sponsored by INGENIA Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
IGT-303
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07231679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231679.